The biliary system is comprised of a series of ducts, organs, and other structures responsible for producing, storing, and transporting bile.

"Biliary tract cancer is comparatively rare, but it's aggressive and spreads fast. Our accrual of more than 450 patients in a little more than two years really shows there is a need for new ways ...

Your digestive system is a group of connected organs that work together to turn the food you eat into nutrients your body needs to function. It includes your biliary system—your gallbladder ...

Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Global Biliary Tract Cancer Market (2024 Edition): Analysis By Indication (Extrahepatic Bile Duct Cancer, Intrahepatic Bile Duct Cancer), By ...

One of the deadliest forms of cancer is biliary tract cancer. Only one in three patients diagnosed with the disease is operable. The rest must settle for life-sustaining treatment.

The incidence rate of biliary tract cancer varies according to geographical regions and subgroups. In recent years, the global prevalence of ICC has increased from 0.44 to 1.18 cases per 100,000 ...

If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract cancer DUBLIN, May 29, 2024 ...

Biliary tract cancers (BTCs)—a group of rare cancers that include cholangiocarcinoma and gallbladder cancer, among others—typically are diagnosed at an advanced stage, with a poor prognosis.

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China, addressing a significant unmet medical need in this patient population.

Nov 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' , opens new tab drug for the treatment of a type of biliary tract cancer, the company said on Wednesday.

Meeting Coverage > GiCS Video Pearls CTX-009/Paclitaxel Yields Responses in Advanced Biliary Tract Cancer — High toxicity, however, needs to be addressed in future trials, says Paul Oberstein, MD ...